3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
1
Phase 1
1
Status
Recruiting
4
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neoplasms
282
Carcinoma, Non-Small-Cell Lung
253
Leukemia, Myeloid, Acute
190
Breast Neoplasms
153
Melanoma
151
Neoplasm Metastasis
148
Multiple Myeloma
127
Recurrence
123
Colorectal Neoplasms
119
Lymphoma, Non-Hodgkin
114
Lymphoma
113
Leukemia, Lymphocytic, Chronic, B-Cell
108
Pancreatic Neoplasms
99
Ovarian Neoplasms
99
Precursor Cell Lymphoblastic Leukemia-Lymphoma
91
Leukemia
86
Prostatic Neoplasms
83
Lung Neoplasms
82
Lymphoma, Large B-Cell, Diffuse
77
Squamous Cell Carcinoma of Head and Neck
76
Glioblastoma
73
Carcinoma, Renal Cell
72
Myelodysplastic Syndromes
68
Lymphoma, Follicular
65
Brain Neoplasms
60
Lymphoma, Mantle-Cell
55
Sarcoma
53
Stomach Neoplasms
52
Head and Neck Neoplasms
52
Triple Negative Breast Neoplasms
51
Interventions
lanreotide
1
Octreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Terminated
×
Gastro-enteropancreatic neuroendocrine tumor
×
Clear all
NCT05364944
2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1
Terminated
19 enrolled